Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity

Cancer Immunol Immunother. 1989;29(4):288-92. doi: 10.1007/BF00199217.

Abstract

Human peripheral blood mononuclear cells (lymphocytes and monocytes) were preincubated for 0-24 h with human recombinant granulocyte-monocyte-colony-stimulating factor (GM-CSF) and used as effector cells in an 18 h antibody-dependent cellular cytotoxicity (ADCC) assay with SW948 (a human colorectal carcinoma cell line) as target cells and mAb 17-1A. A significant increase in the lytic capability was noted after 0.5-2 h of preactivation while longer preincubation times did not significantly increase the lytic potential. GM-CSF at 0.01 microgram/ml induced the best tumor cell lysis while higher concentrations were inhibitory. GM-CSF pretreatment induced a statistically significant increase in the lytic capacity of both monocytes and lymphocytes in ADCC as well as in the spontaneous cytotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibody-Dependent Cell Cytotoxicity / drug effects*
  • Antigens, Differentiation / analysis
  • Cells, Cultured
  • Colony-Stimulating Factors / pharmacology*
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Growth Substances / pharmacology*
  • Humans
  • In Vitro Techniques
  • Leukocytes, Mononuclear / classification
  • Leukocytes, Mononuclear / immunology
  • Lymphocytes / classification
  • Lymphocytes / immunology*
  • Monocytes / classification
  • Monocytes / immunology*

Substances

  • Antibodies, Monoclonal
  • Antigens, Differentiation
  • Colony-Stimulating Factors
  • Growth Substances
  • Granulocyte-Macrophage Colony-Stimulating Factor